Archives
-
D-Luciferin for BLI in Glioblastoma Research
2026-09-30
D-Luciferin potassium salt enables real-time, non-invasive tracking of luciferase-labeled tumor cells and treatment response in preclinical models. This guide connects reliable BLI workflows with the macrophage membrane-camouflaged nanoparticle strategy reported for glioblastoma, while separating optical viability measurements from nanoparticle biodistribution.
-
Lisinopril Dihydrate: Assay Logic
2026-09-30
Lisinopril dihydrate is a long-acting ACE inhibitor whose value extends beyond blood-pressure models. This article explains how to use it as an interpretable mechanistic probe, integrating product chemistry with comparative peptidase evidence and assay-design decisions.
-
Honokiol Workflows for Better Cancer Assays
2026-09-29
Honokiol can be evaluated as an NF-κB pathway inhibitor, antioxidant, and antiangiogenic research compound—but only if growth arrest and cell killing are measured separately. This workflow combines controlled solvent handling, time-resolved viability testing, ROS readouts, and orthogonal validation for more interpretable cancer and inflammation studies.
-
Angiotensin II: Practical Research Workflow
2026-09-29
This guide explains how to use Angiotensin II as a controlled receptor agonist for vascular signaling, oxidative-stress, and remodeling workflows. It provides product-dossier starting conditions for cell and animal studies, but it is not a substitute for study-specific optimization, validated disease protocols, or diagnostic or medical use.
-
Electrical Stimulation Boosts Nanoparticle Endocytosis
2026-09-28
The reference study demonstrates that alternating-current electrical stimulation can enhance magnetic nanoparticle uptake by cancer cells without requiring particle-surface functionalization. Its combination of uptake quantification, imaging, cytoskeletal analysis, and functional magnetic hyperthermia and MRI assays links a macropinocytic mechanism to improved biomedical performance.
-
ATRX Loss Sensitizes Glioma Cells to RTK Inhibitors
2026-09-28
A 2022 drug-screening study found that ATRX-deficient high-grade glioma cells were more sensitive to several receptor tyrosine kinase and PDGFR inhibitors than comparator cells. It also reported pronounced toxicity when selected RTK inhibitors were combined with temozolomide, supporting ATRX status as a relevant variable for preclinical studies and clinical-trial analyses—not as a validated treatment-selection rule.
-
Caspase-3 Fluorometric Assay Kit: Applied Workflow
2026-09-27
Track downstream DEVD-cleaving activity in treatment and control samples with a rapid fluorescence workflow. Applied to hyperthermia–cisplatin models, the assay complements pathway and cell-death measurements while keeping clear boundaries between caspase-3 activity and proof of pyroptosis.
-
P2RX1 and Mitochondrial Apoptosis in Ph+ ALL
2026-09-26
Li et al. report that P2RX1 overexpression sensitizes SUP-B15 Philadelphia chromosome-positive acute lymphoblastic leukemia cells to tyrosine kinase inhibitor–induced apoptosis, alongside calcium disruption, CaMKII activation, and reduced PI3K/Akt signaling. The findings outline a candidate mitochondrial cell-death mechanism, but the clinical association and single-cell-line experiments do not establish P2RX1 as a validated treatment target or response biomarker.
-
Ferrostatin-1 in Ferroptosis Assay Design
2026-09-25
Use Ferrostatin-1 (Fer-1) as a mechanistic rescue control to test whether lipid peroxidation contributes to cell injury—not as a universal ROS or cell-death inhibitor. This workflow pairs dose-matched rescue experiments with pathway-specific readouts and applies an important distinction from a lung epithelial bystander-death study: ROS production alone does not establish ferroptosis.
-
BIRB 796: Reading p38 Inhibition Over Time
2026-09-25
BIRB 796 (Doramapimod) is a potent allosteric p38α inhibitor, but its effects on kinase activity and activation-loop phosphorylation are not interchangeable. This article connects recent phosphatase findings to practical assay design, showing how to interpret p38 signaling over time without assuming that every inhibitor produces the same dephosphorylation response.
-
Ricin-Driven Bystander Necroptosis in Lung Epithelium
2026-09-24
Kempen and colleagues report that factors released by ricin-treated monocytic cells can trigger necroptosis in neighboring lung epithelial cells, with ricin, Fas ligand, and HMGB1 implicated in the response. The findings connect toxin injury to bystander inflammation and suggest experimental ways to distinguish this pathway from apoptosis or other forms of cell death.
-
Angiotensin 1/2 (1-6): From RAS to Receptor Biology
2026-09-23
Explore how the Asp-Arg-Val-Tyr-Ile-His angiotensin fragment can connect renin-angiotensin system research with emerging receptor-binding questions—and how to design translational studies without overstating the evidence.
-
BFH772 (VEGFR2 inhibitor): Workflow Guide
2026-09-23
BFH772 is a selective small-molecule VEGFR2 inhibitor for controlled studies of VEGFR2-driven signaling and angiogenesis, including tumor angiogenesis research. Its water insolubility and organic-solvent formulation mean it should not be used in workflows that require an aqueous stock or broad-spectrum kinase inhibition without additional formulation and selectivity controls.
-
Fluoxetine HCl and the Biology of Motivation
2026-09-22
A translational framework for using Fluoxetine HCl to connect serotonergic target engagement with neuroplasticity, reward behavior, and developmental SSRI research without confusing molecular activity with clinical outcome.
-
Rotigotine hydrochloride in Depression Models
2026-09-22
Rotigotine hydrochloride is a dopamine D2/D3 receptor agonist that can connect antiparkinsonian pharmacology with behavioral models of depression. This guide translates published dose-response findings into practical cell, rodent, formulation, and troubleshooting workflows.